Reassessing Repligen (RGEN) Valuation After A Steep Multi‑Month Share Price Pullback

Repligen stock reaction and recent performance

Repligen (RGEN) continues to trade in focus after recent share price moves, with the stock closing at $104.20 and sitting against a backdrop of mixed short- and longer-term returns.

Over the past week the stock fell about 10%, and it is down around 21% over the past month and 23% over the past 3 months, with the year-to-date return down roughly 37%.

See our latest analysis for Repligen.

With a 1-day share price return of 1.29% but a year-to-date share price return down 36.6%, momentum has been fading. This aligns with the 1-year total shareholder return down 17.43% and the 3-year total shareholder return down 37.51%.

If Repligen’s recent pullback has you reassessing where to put fresh capital, it can help to compare it alongside other high growth themes using our 31 healthcare AI stocks

With the stock trading below some valuation estimates yet sitting on weak recent returns, investors may need to consider whether Repligen is attractively priced after a rough stretch or whether the market already reflects its future growth potential.

Most Popular Narrative: 43.3% Undervalued

Repligen’s most followed valuation narrative puts fair value at $183.88, well above the recent $104.20 close, and ties that gap to specific growth and profitability assumptions.

Strong and sustained order growth across biopharma, CDMO, and capital equipment segments, supported by record multi-quarter book-to-bill ratios and a robust funnel, positions the company for above-market revenue increases as therapy pipelines expand and demand for advanced bioprocessing solutions rises. Repligen is investing in expanding dual manufacturing in the U.S. and Europe and increasing APAC presence to address growing customer demand for greater supply chain security and regionalization. These factors are expected to support resilient sales globally and reduce revenue concentration risk.

Read the complete narrative.

Curious what kind of revenue curve and margin profile need to line up to support that valuation gap? The narrative leans on ambitious earnings compounding and a premium future earnings multiple that stands well above typical sector benchmarks, all tied to detailed assumptions on product mix, global footprint, and capital allocation.

Result: Fair Value of $183.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat narrative still depends on biotech funding and gene therapy demand stabilizing, as well as on higher cost investments not compressing margins if orders disappoint.

Find out about the key risks to this Repligen narrative.

Another angle on valuation

While the analyst fair value of $183.88 points to Repligen looking undervalued, the current P/E of 114.4x tells a very different story. It sits well above the estimated fair ratio of 24.3x, the Global Life Sciences average of 34.4x and the peer average of 38.8x, which means a lot has to go right for today’s price to hold up if sentiment cools.

For a closer look at what those P/E gaps could mean for valuation risk or opportunity, check the detailed breakdown in our See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

After all this mixed sentiment, the key question is what it means for you right now. Move quickly, review the details, and weigh up the 4 key rewards.

Looking for more investment ideas?

If Repligen no longer feels like the only stock on your radar, now is the time to broaden your watchlist and pressure test your next move.

• Target long term opportunities by scanning high quality companies that look potentially mispriced using the 52 high quality undervalued stocks.
• Prioritise resilience by focusing on companies with stronger finances through the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for lesser known opportunities that still show solid fundamentals with the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com